First patient dosed in AXT107 clinical trial for DME

The first patient has been dosed in a phase 1/2a clinical trial of AXT107 to evaluate the safety and bioactivity of the therapy in patients with diabetic macular edema, according to a press release from AsclepiX Therapeutics.
CONGO, an open-label, dose-escalating, 48-week trial, will evaluate a single intravitreal injection of AXT107 at a low dose of 0.1 mg, a mid-dose of 0.25 mg or a high dose of 0.5 mg in approximately 18 patients.
An investigational new drug application for AXT107 was cleared by the FDA in December for the (Read more...)

Full Story →